TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04545502

Intervention type: DEVICE
Intervention: Gelsoft Plus Vascular Graft
Description: Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.

Intervention type: DEVICE
Intervention: Vascular Bypass Graft
Description: Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.

Intervention type: DEVICE
Intervention: Cardiovascular Patch
Description: Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.

Intervention type: DEVICE
Intervention: Gelweave Vascular Graft
Description: The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.

Intervention type: DEVICE
Intervention: Gelweave Valsalva Vascular Graft
Description: This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
Study: NCT04842968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylene blue injection
Description: Methylene blue solution is injected ex vivo in the main supplying artery trunk of the freshly removed colorectal specimen. (50 mg in 30 ml saline)
Study: NCT05568719

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Testing of hepatic AAV Vector integration
Description: Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Testing of hepatic AAV Vector integration
Description: Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
Study: NCT06066424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TROP2-CAR-NK Cells
Description: Given by (IV) vein
Study: NCT05742958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Description: The study will be conducted in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery under spinal anesthesia. In this arm, 0.1 mg intrathecal morphine in addition to spinal anesthesia will be used for perioperative pain management. A placebo addctor canal block will also be performed for masking in these patients. The quality of recovery will be evaluated with a postoperative quality of recovery scale (QoR-40 questionnaire) at postoperative 24-hour and 14-day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: After providing complete sensory block in the lower extremities with spinal anesthesia, the thigh where the surgery will be performed will be brought into slight abduction and external rotation while the patient is in the supine position. The blockage of the saphenous nerve in the adductor canal will be performed with 30 mL of local anesthetic (0.25% bupivacaine) solution with a 22 gauge 5-8 cm long block needle from the mid-medial part of the thigh under ultrasound guidance. The quality of recovery will be evaluated with QoR-40 questionnaire at postoperative 24-hour and 14-day.
Study: NCT05884710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot core exercises
Description: 2 groups; First group is an intervention group who has contain foot core exercises and the other group is a control group.
Study: NCT06643533

Intervention type: OTHER
Intervention: Fecal Microbiota Transplantation
Description: The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle. The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W). The duration of the treatment will be determined by the response to therapy, with a maximum of 6 cycles or until disease progression, intolerable toxicity, or participant withdrawal of consent. The FMT capsules are intended to modify the gut microbiome to reverse the resistance to the triple therapy and enhance the therapeutic response.
Study: NCT04878471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pudexacianinium chloride
Description: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous
Study: NCT06373718

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
Study: NCT05884710

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Electrotherapeutic modalities and range of motion exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Electrotherapeutic modalities and range of motion exercises
Study: NCT04526080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic Device
Description: Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
Study: NCT05456451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive vagus nerve srimulation
Description: Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
Study: NCT04960761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention Group
Description: In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied.
Study: NCT06475274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-035
Description: Protein, a recombinant variant of A1M. Concentrate for solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-035
Description: Protein, a recombinant variant of A1M. Concentrate for solution for infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to RMC-035 intervention devoid of the active substance.
Study: NCT04846881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin
Description: Iclepertin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06387719

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: * Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: * Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles.
Study: NCT06066424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TROP2-CAR-NK Cells
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TROP2-CAR-NK Cells
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by (IV) vein
Study: NCT06373718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
Study: NCT06066424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by (IV) vein
Study: NCT06527872

Intervention type: OTHER
Intervention: None (Observational study)
Description: Not Applicable since Observational Study
Study: NCT06066424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by (IV) vein
Study: NCT06233630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Test - spinal anesthesia
Description: No peripheral nerve block Only spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution ESPB
Description: ultrasound guided erector spinae plane block (ESPB) - L2 level, unilateral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution iPACK+ACB
Description: ultrasound guided iPACK block + Adductor Canal Block
Study: NCT06042920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05905055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-administration of cefepime and nacubactam
Description: 2 g cefepime and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-administration of aztreonam and nacubactam
Description: 2 g aztreonam and 1 g nacubactam every 8 hours for at least 5 days and up to 14 days via IV infusion over a period of 60 minutes
Study: NCT05861310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 1% Cream,Top
Description: Cream that has an active ingredient in the form of metronidazole with a content of 1%. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the participants were given metronidazole 1% cream which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cream that has not medicine. At the beginning of the study visit, anamnesis and examination of the skin status were carried out. Skin status includes examination of the degree of erythema with a Clinician Erythema Assessment Scale (CEA) score, examination of skin scrapings for demodex examination, dermoscopy examination, and TEWL (Transepidermal Water Loss) examination. Then the research subjects were given Placebo cream (without the drug substance) which was to be used twice a day in the morning and at night. Evaluation of the therapeutic response will be carried out on days 28 and days 56.
Study: NCT05580887

Intervention type: DRUG
Intervention: mFOLFIRINOX
Description: every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.

Intervention type: DRUG
Intervention: Doxorubicin
Description: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles

Intervention type: DRUG
Intervention: Cyclophosphamid
Description: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles

Intervention type: DRUG
Intervention: Paclitaxel
Description: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles

Intervention type: DRUG
Intervention: Carboplatin
Description: dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
Study: NCT05714241

Intervention type: OTHER
Intervention: Data extraction
Description: After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm).

Intervention type: OTHER
Intervention: Blood sampling
Description: At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.

Intervention type: OTHER
Intervention: Clinical Follow-up
Description: All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected.
Study: NCT05913817

Intervention type: BIOLOGICAL
Intervention: AVT02 (Alvotech Biosimilar to Adalimumab)
Description: Phase IV Study

Intervention type: BIOLOGICAL
Intervention: AVT02 (Alvotech Biosimilar to Adalimumab)
Description: Phase IV Study
Study: NCT05685550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toposide capsules combined with anrotinib and Emvolizumab group
Description: Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
Study: NCT04584086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 tesla
Description: 1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)~In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:~* During treatment when half of the prescribed dose has been delivered.~* 1 month after the end of the irradiation.
Study: NCT06298890

Intervention type: DEVICE
Intervention: Artificial tears (sodium hyaluronate 0.2%)
Description: Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.
Study: NCT05215990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive metformin with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: studying about acid-fast bacillus sputum conversion ratio from positive to negative of pulmonary tuberculosis patients receive placebo drug with pulmonary tuberculosis standard treatment group in second week, second, fifth, and sixth month.
Study: NCT05210231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The direct electric current will be applied through a pair of sponges humidified with saline solution (150 mMols of NaCl diluted in water Milli-Q) on the electrodes (35 cm2). The electrodes (anode and cathode) will be connected to a continuous electric stimulator (Model: Microestim Foco Research, Brand: NKL, Souza Cruz, Brusque - SC, Brazil), with one energy battery (9 V) and will be mounted in accordance with the International 10-20 EEG System. For anodal polarity stimulation over the left TC, the anodal electrode will be placed over the scalp on the T3 area located at 40% of the distance on the left from the Cz point. The cathode electrode will be placed over the contralateral supraorbital area (Fp2). Thereafter, a constant electric current of 2 mA will be applied for 20 min.
Study: NCT04890431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)
Study: NCT06008028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-1
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1015-2
Description: One tablet administered alone
Study: NCT05562622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of lenses may reduce the rate of progression of juvenile myopia

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacle lenses
Description: Use of lenses may reduce the rate of progression of juvenile myopia
Study: NCT06419582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg taken once daily for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily for 21 days
Study: NCT06048848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.